肿瘤突变负荷预测BRAF突变微卫星稳定转移性结直肠癌对EGFR/BRAF阻断的耐药
这项多中心病例对照研究比较了BRAF突变/MSS转移性结直肠癌原发耐药组(20例)与敏感组(19例)的基因组和表达谱,发现耐药组TMB及中等TMB比例更高,且中等TMB患者PFS和OS更短;左半肿瘤在敏感组更富集,CCND1-3扩增仅见于耐药组。
要点
- 耐药组中位TMB为6(IQR 3-7.29),敏感组为3(IQR 1.26-3.5),P=0.013。
- 中等TMB(TMB-I 6-20突变/Mb)比例耐药组60% vs 敏感组11%,P=0.001。
- TMB-I患者PFS 3.3 vs 5.9个月(HR=2.19,95%CI 1.07-4.47),OS 6.3 vs 10.5个月(HR=2.22,95%CI 1.02-4.81)。
核心结论
- 尽管样本量小,相对较高的TMB与BRAF突变/MSS转移性结直肠癌患者从EGFR/BRAF阻断中获益有限相关,值得前瞻性验证。
研究设计与样本
- 多中心病例对照研究,纳入接受EGFR/BRAF±MEK阻断治疗的患者,原发耐药组20例(RECIST v1.1 PD/SD且PFS<16周),敏感组19例(RECIST v1.1 PR/CR且PFS≥16周)。
- 采用全面基因组分析、肿瘤突变负荷(TMB)、BRAF突变转录亚型(BM)分类和PTEN表达进行比较。
主要发现
- 左半肿瘤占总数的28%,在敏感组 vs 耐药组分别为53% vs 10%,P=0.010。
- PIK3CA/MTOR通路基因改变、BM1状态和PTEN丢失在耐药与敏感组间分布相似。
- CCND1-3基因扩增仅见于原发耐药患者(20% vs 0%,P=0.106)。
- 耐药组 vs 敏感组中位TMB为6(IQR 3-7.29) vs 3(IQR 1.26-3.5),P=0.013;中等TMB(TMB-I 6-20突变/Mb)比例60% vs 11%,P=0.001。
- TMB-I患者PFS为3.3 vs 5.9个月(HR=2.19,95%CI 1.07-4.47,P=0.031),OS为6.3 vs 10.5个月(HR=2.22,95%CI 1.02-4.81,P=0.044)。
局限性
- 样本量小。
- 研究结论值得前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To unveil genomic and immunohistochemical expression profiles associated with primary resistance to EGFR/BRAF targeted therapy in patients with BRAF-mutated and microsatellite stable (MSS) metastatic colorectal cancer. EXPERIMENTAL DESIGN: In this multicenter case-control study on patients treated with EGFR/BRAF ± MEK blockade, we compared a primary resistance cohort (N = 20; RECISTv1.1 PD/SD, and progression-free survival [PFS] <16 weeks) versus a sensitive one (N = 19; RECISTv1.1 PR/CR, and PFS ≥16 weeks) in terms of clinical and genomic/expression data by means of comprehensive genomic profiling, tumour mutational burden (TMB), BRAF-mutant transcriptional subtypes (BM) classification and PTEN expression. RESULTS: Left-sided tumours (28% of the total) were enriched in the sensitive versus resistant cohort (53% versus 10%, P = 0.010). Genomic alterations in the PIK3CA/MTOR pathway, BM1 status and PTEN loss were similarly distributed among patients with resistant and sensitive tumours. Amplification of CCND1-3 genes were found only in patients with primary resistance (20% versus 0%, P = 0.106). TMB and prevalence of intermediate TMB (TMB-I 6-20 mutations/Mb) were higher in the resistant versus sensitive cohort (median TMB: 6 [IQR, 3-7.29] versus 3 [IQR, 1.26-3.5]; P = 0.013; TMB-I/H: 60% versus 11%; P = 0.001). Patients with TMB-I had shorter PFS (3.3 versus 5.9 months; HR = 2.19, 95%CI, 1.07-4.47, P = 0.031) and overall survival (6.3 versus 10.5 months; HR = 2.22, 95%CI, 1.02-4.81, P = 0.044). CONCLUSION: Despite the small sample size, the association of a relatively higher TMB with limited benefit from EGFR/BRAF blockade in patients with MSS and BRAF-mutated mCRC deserves prospective validation.
引用
- Randon G, Intini R, Cremolini C, et al. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. Eur J Cancer. 2021. PMID: 34933155. doi:10.1016/j.ejca.2021.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。